Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?

Abstract : Although CD95L (also known as FasL) is still predominantly considered as a death ligand that induces apoptosis in infected and transformed cells, substantial evidence indicate that it can also trigger non-apoptotic signaling pathways whose pathophysiological roles remain to be fully elucidated. The transmembrane ligand CD95L belongs to the tumor necrosis factor (TNF) superfamily. After cleavage by metalloprotease, its soluble form (s-CD95L) fails to trigger the apoptotic program but instead induces signaling pathways promoting the aggressiveness of certain inflammatory disorders such as autoimmune diseases and cancers. We propose to evaluate the various pathologies in which the metalloprotease-cleaved CD95L is accumulated and analyze whether this soluble ligand may play a significant role in the pathology progression. Based on the TNFα-targeting therapeutics, we envision that targeting the soluble form of CD95L may represent a very attractive therapeutic option in the pathologies depicted herein.
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Laurent Jonchère Connectez-vous pour contacter le contributeur
Soumis le : jeudi 16 septembre 2021 - 11:35:10
Dernière modification le : vendredi 17 septembre 2021 - 10:22:03


 Accès restreint
Fichier visible le : 2022-01-26

Connectez-vous pour demander l'accès au fichier



Keerthi Kurma, Andrea Boizard-Moracchini, Gael Galli, Mickael Jean, Pierre Vacher, et al.. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Elsevier, 2021, 1876 (2), pp.188596. ⟨10.1016/j.bbcan.2021.188596⟩. ⟨hal-03333846⟩



Consultations de la notice